Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by HighteawithIntrepidon Nov 11, 2017 4:46pm
255 Views
Post# 26945945

RE:RE:RE:RE:Esbriet’s Efficacy in Severe IPF Seen to Diminish 6-12 Month

RE:RE:RE:RE:Esbriet’s Efficacy in Severe IPF Seen to Diminish 6-12 MonthBig Pharma would not short a potential target. They
would hire persons unknown to talk the Stock down while at
the same time nibbling at 9.9999% or slightly more than 70 million shares.
Then a takeover at 5.00 after the next FDA yes is a more likely scenario 
The shorting started at over 3.00 a little late for the conscripts but
why they have not been covering since the Thomvest back up
funding is the big mystery. Within 50 hours we will have the Q3 news and perhaps 
another piece of the where do we go from here puzzle.
Bullboard Posts